Results of Ascierto et al., obtained with the use of BEAMing technology, confirmed the abovementioned data, finding a relation between baseline and follow-up BRAF(V600E) ctDNA levels and tumor burden, response to treatment with BRAF inhibitors, prediction of disease progression prior to CT scan, and PFS. This evidence concerns the gene BRAF and neoplasm.